References

  1. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. PMID: 27718784; PMCID: PMC5564292.
  2. Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and Immunotherapy for Cancer: From ”Systemic” to ”Multisite”. Clin Cancer Res. 2020 Jun 15;26(12):2777-2782. doi: 10.1158/1078-0432.CCR-19-2034. Epub 2020 Feb 11. PMID: 32047000.
  3. Daguenet E, Louati S, Wozny AS, Vial N, Gras M, Guy JB, et al., Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer. 2020 Aug;123(3):339-348. doi: 10.1038/s41416-020-0942-3. Epub 2020 Jun 25. PMID: 32581341; PMCID: PMC7403362.
  4. Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, et al., Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021 Nov;2(11):1124-1135. doi: 10.1038/s43018-021-00269-7. Epub 2021 Nov 18. PMID: 35122060; PMCID: PMC8809884.
  5. Qian JM, Schoenfeld JD. Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. Front Oncol. 2021 Feb 3;10:608772. doi: 10.3389/fonc.2020.608772. PMID: 33614492; PMCID: PMC7886974.
  6. McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al., Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2021 Jan 1;39(1):30-37. doi: 10.1200/JCO.20.00290. Epub 2020 Aug 21. PMID: 32822275; PMCID: PMC8462641.
  7. Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, et al., Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 2021 May;9(5):e002485. doi: 10.1136/jitc-2021-002485. PMID: 33963014; PMCID: PMC8108690.
  8. Botticelli A, Mezi S, Pomati G, Sciattella P, Cerbelli B, Roberto M, et al., The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines (Basel). 2020 Apr 20;8(2):191. doi: 10.3390/vaccines8020191. PMID: 32326034; PMCID: PMC7349768.